Nov 5, 4:07 PM ET
Effective July 1, 2026, Bruker reorganized its reportable segments, with BSI BIOS, BSI BMID, BSI NANO and BEST now reported. The company furnished recast segment data for 2024, 2025 and 2026 periods so investors can compare on the new basis. The filing states the change has no effect on historical consolidated results of operations, financial position or cash flows, and is not a restatement.
- Reorganization effective July 1, 2026 creates four reportable segments: BSI BIOS, BSI BMID, BSI NANO and BEST.
- Exhibit 99.1 provides recast segment data for fiscal 2025 and 2024, quarterly 2025 and 2026 periods, and the nine months ended September 30, 2025.
- Fiscal 2025 revenue from external customers is $3.4 billion on both the as-reported and recast bases, per the exhibit.
Read the filing on SEC.gov ↗
Nov 4, 7:00 AM ET
Bruker reported third-quarter 2026 revenue of $874.0 million, up 1.6% from a year earlier, and non-GAAP diluted EPS of $0.56, up 24.4%. GAAP results were a diluted loss of $(0.81) per share, driven by a $174.5 million goodwill impairment charge, and the company reconfirmed its FY26 organic revenue growth and non-GAAP EPS guidance of $2.10 to $2.15.
- Q3-26 revenue $874.0 million, up 1.6% yoy; organic growth 0.7%
- Q3-26 non-GAAP diluted EPS $0.56, up 24.4% from $0.45; GAAP diluted loss $(0.81) vs. $(0.41) a year earlier
- Q3-26 GAAP operating loss $(91.0) million, including a $174.5 million goodwill impairment charge
- FY26 non-GAAP EPS outlook of $2.10 to $2.15 reconfirmed; FY26 revenue guidance $3.52 to $3.56 billion
Read the filing on SEC.gov ↗
Oct 29, 4:05 PM ET
Bruker Corporation's board declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable December 1, 2026, to holders of record at the close of business on November 15, 2026. This is a routine dividend declaration that sets the payment and record dates for preferred shareholders.
- Dividend of $3.9844 per share declared October 29, 2026
- Payable December 1, 2026
- Record date is the close of business on November 15, 2026
Read the filing on SEC.gov ↗
Aug 4, 7:00 AM ET
Bruker reported second-quarter 2026 revenue of $838.5 million, up 5.2% year over year, and non-GAAP diluted EPS of $0.49, up from $0.32. A $134.9 million goodwill impairment produced a GAAP diluted loss of $(0.41) per share, and FY26 non-GAAP EPS guidance of $2.10 to $2.15 was kept, with the outlook updated only for currency and tax.
- Q2 revenue of $838.5 million, up 5.2%; organic growth was 2.8%, or 3.4% excluding tariff refunds
- GAAP diluted loss of $(0.41) per share versus $0.05 a year earlier, including a $134.9 million goodwill impairment charge
- Non-GAAP diluted EPS of $0.49 versus $0.32; non-GAAP operating margin of 14.1% versus 9.0%
- FY26 non-GAAP EPS guidance of $2.10 to $2.15 unchanged; currency tailwind to revenue cut to approximately 0.5% from 1.5%
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.